vs
MILLER INDUSTRIES INC（MLR）与VERACYTE, INC.（VCYT）财务数据对比。点击上方公司名可切换其他公司
MILLER INDUSTRIES INC的季度营收约是VERACYTE, INC.的1.2倍（$171.9M vs $139.1M），VERACYTE, INC.同比增速更快（21.5% vs -22.5%），过去两年VERACYTE, INC.的营收复合增速更高（10.2% vs -29.9%）
米勒工业是一家总部位于美国田纳西州奥尔特瓦的清障拖车及拖拽设备制造企业，旗下核心子公司米勒工业拖拽设备有限公司，以世纪、福尔坎、雪佛龙、霍姆斯等多个品牌生产从轻型到重型的各类清障车、车辆运输车和旋转吊装清障车，同时还运营英国邦尼费斯、法国吉格等国际品牌，在纽约证券交易所挂牌上市。
Veracyte是一家领先的分子诊断企业，专注开发专有的基因组检测方案，可实现癌症及其他复杂疾病的早期精准检测，产品服务于医疗机构以优化临床决策，核心市场位于美国，正稳步拓展全球业务布局。
MLR vs VCYT — 直观对比
营收规模更大
MLR
是对方的1.2倍
$139.1M
营收增速更快
VCYT
高出44.0%
-22.5%
两年增速更快
VCYT
近两年复合增速
-29.9%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $171.9M | $139.1M |
| 净利润 | — | $28.7M |
| 毛利率 | 15.4% | 72.7% |
| 营业利润率 | 2.9% | 16.3% |
| 净利率 | — | 20.6% |
| 营收同比 | -22.5% | 21.5% |
| 净利润同比 | — | — |
| 每股收益（稀释后） | $0.29 | $0.35 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MLRVCYT
| Q1 26 | — | $139.1M | ||
| Q4 25 | $171.9M | $140.6M | ||
| Q3 25 | $178.7M | $131.9M | ||
| Q2 25 | $214.0M | $130.2M | ||
| Q1 25 | $225.7M | $114.5M | ||
| Q4 24 | $221.9M | $118.6M | ||
| Q3 24 | $314.3M | $115.9M | ||
| Q2 24 | $371.5M | $114.4M |
净利润MLRVCYT
| Q1 26 | — | $28.7M | ||
| Q4 25 | — | $41.1M | ||
| Q3 25 | $3.1M | $19.1M | ||
| Q2 25 | $8.5M | $-980.0K | ||
| Q1 25 | $8.1M | $7.0M | ||
| Q4 24 | — | $5.1M | ||
| Q3 24 | $15.4M | $15.2M | ||
| Q2 24 | $20.5M | $5.7M |
毛利率MLRVCYT
| Q1 26 | — | 72.7% | ||
| Q4 25 | 15.4% | 72.5% | ||
| Q3 25 | 14.2% | 69.2% | ||
| Q2 25 | 16.2% | 69.0% | ||
| Q1 25 | 15.0% | 69.5% | ||
| Q4 24 | 15.1% | 66.4% | ||
| Q3 24 | 13.4% | 68.2% | ||
| Q2 24 | 13.8% | 68.1% |
营业利润率MLRVCYT
| Q1 26 | — | 16.3% | ||
| Q4 25 | 2.9% | 26.4% | ||
| Q3 25 | 2.4% | 17.4% | ||
| Q2 25 | 5.3% | -4.0% | ||
| Q1 25 | 4.8% | 2.5% | ||
| Q4 24 | 5.7% | 3.5% | ||
| Q3 24 | 6.3% | 10.4% | ||
| Q2 24 | 7.1% | 4.0% |
净利率MLRVCYT
| Q1 26 | — | 20.6% | ||
| Q4 25 | — | 29.3% | ||
| Q3 25 | 1.7% | 14.5% | ||
| Q2 25 | 4.0% | -0.8% | ||
| Q1 25 | 3.6% | 6.2% | ||
| Q4 24 | — | 4.3% | ||
| Q3 24 | 4.9% | 13.1% | ||
| Q2 24 | 5.5% | 5.0% |
每股收益（稀释后）MLRVCYT
| Q1 26 | — | $0.35 | ||
| Q4 25 | $0.29 | $0.50 | ||
| Q3 25 | $0.27 | $0.24 | ||
| Q2 25 | $0.73 | $-0.01 | ||
| Q1 25 | $0.69 | $0.09 | ||
| Q4 24 | $0.89 | $0.07 | ||
| Q3 24 | $1.33 | $0.19 | ||
| Q2 24 | $1.78 | $0.07 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $439.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $420.6M | $1.3B |
| 总资产 | $589.7M | $1.4B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资MLRVCYT
| Q1 26 | — | $439.1M | ||
| Q4 25 | — | $362.6M | ||
| Q3 25 | — | $315.6M | ||
| Q2 25 | — | $219.5M | ||
| Q1 25 | — | $186.1M | ||
| Q4 24 | — | $239.1M | ||
| Q3 24 | — | $274.1M | ||
| Q2 24 | — | $235.9M |
股东权益MLRVCYT
| Q1 26 | — | $1.3B | ||
| Q4 25 | $420.6M | $1.3B | ||
| Q3 25 | $420.7M | $1.3B | ||
| Q2 25 | $418.6M | $1.2B | ||
| Q1 25 | $406.5M | $1.2B | ||
| Q4 24 | $401.0M | $1.2B | ||
| Q3 24 | $395.2M | $1.2B | ||
| Q2 24 | $379.9M | $1.1B |
总资产MLRVCYT
| Q1 26 | — | $1.4B | ||
| Q4 25 | $589.7M | $1.4B | ||
| Q3 25 | $604.3M | $1.4B | ||
| Q2 25 | $622.9M | $1.3B | ||
| Q1 25 | $639.7M | $1.3B | ||
| Q4 24 | $667.0M | $1.3B | ||
| Q3 24 | $755.3M | $1.3B | ||
| Q2 24 | $748.2M | $1.2B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $48.9M | $35.2M |
| 自由现金流经营现金流 - 资本支出 | $43.8M | — |
| 自由现金流率自由现金流/营收 | 25.5% | — |
| 资本支出强度资本支出/营收 | 3.0% | — |
| 现金转化率经营现金流/净利润 | — | 1.23× |
| 过去12个月自由现金流最近4个季度 | $85.0M | — |
8季度趋势，按日历期对齐
经营现金流MLRVCYT
| Q1 26 | — | $35.2M | ||
| Q4 25 | $48.9M | $52.6M | ||
| Q3 25 | $19.9M | $44.8M | ||
| Q2 25 | $27.2M | $33.6M | ||
| Q1 25 | $2.7M | $5.4M | ||
| Q4 24 | $-11.7M | $24.5M | ||
| Q3 24 | $30.3M | $30.0M | ||
| Q2 24 | $-10.7M | $29.6M |
自由现金流MLRVCYT
| Q1 26 | — | — | ||
| Q4 25 | $43.8M | $48.8M | ||
| Q3 25 | $18.1M | $42.0M | ||
| Q2 25 | $25.6M | $32.3M | ||
| Q1 25 | $-2.4M | $3.5M | ||
| Q4 24 | $-13.0M | $20.4M | ||
| Q3 24 | $24.0M | $27.7M | ||
| Q2 24 | $-13.8M | $26.8M |
自由现金流率MLRVCYT
| Q1 26 | — | — | ||
| Q4 25 | 25.5% | 34.7% | ||
| Q3 25 | 10.1% | 31.8% | ||
| Q2 25 | 11.9% | 24.8% | ||
| Q1 25 | -1.1% | 3.1% | ||
| Q4 24 | -5.9% | 17.2% | ||
| Q3 24 | 7.6% | 23.9% | ||
| Q2 24 | -3.7% | 23.4% |
资本支出强度MLRVCYT
| Q1 26 | — | — | ||
| Q4 25 | 3.0% | 2.7% | ||
| Q3 25 | 1.0% | 2.1% | ||
| Q2 25 | 0.8% | 1.0% | ||
| Q1 25 | 2.3% | 1.6% | ||
| Q4 24 | 0.6% | 3.5% | ||
| Q3 24 | 2.0% | 1.9% | ||
| Q2 24 | 0.8% | 2.4% |
现金转化率MLRVCYT
| Q1 26 | — | 1.23× | ||
| Q4 25 | — | 1.28× | ||
| Q3 25 | 6.46× | 2.34× | ||
| Q2 25 | 3.22× | — | ||
| Q1 25 | 0.34× | 0.76× | ||
| Q4 24 | — | 4.80× | ||
| Q3 24 | 1.96× | 1.98× | ||
| Q2 24 | -0.52× | 5.16× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MLR
暂无分部数据
VCYT
| Testing revenue | $135.1M | 97% |
| Product revenue | $3.7M | 3% |
| Biopharmaceutical and other revenue | $301.0K | 0% |
